AstraZeneca’s Alexion Signs $825 Million Gene Therapy Licensing Deal with JCR Pharmaceuticals

AstraZeneca’s rare disease division, Alexion, has finalized a license agreement with JCR Pharmaceuticals valued at up to $825 million. The arrangement allows Alexion to utilize JCR’s proprietary adeno-associated virus (AAV) capsids from the JUST-AAV platform in the development of genomic medicines across five of its programs.
The financial terms include an undisclosed upfront payment from Alexion to JCR, along with potential development-related milestone payments of up to $225 million and sales-based milestones reaching $600 million. If all five therapy programs advance to market, the combined payments could total $825 million. JCR will also receive tiered royalties based on net product sales.

The licensed capsids originate from JCR’s JUST-AAV vector platform. This technology is engineered to improve the targeted delivery of gene therapies. The capsid variants include those designed to bypass the liver and those that focus on delivery to muscle tissue or the brain. The platform involves engineering miniaturized antibodies against specific receptors on the surface of the AAV capsids, enabling improved delivery to selected tissues, organs, or across the blood-brain barrier. Additional modifications are included to reduce off-target effects and enhance safety.
According to JCR, the acronym JUST-AAV reflects key features of the platform: “JCR,” “Ultimate destination of organ,” “Safeguarding against off-target delivery,” and “Transformative technology.” The platform is designed to enable a broad range of gene therapy applications.
Shin Ashida, Chairman, President, and CEO of JCR Pharmaceuticals, stated, “I am very pleased to announce the signing of this license agreement for our proprietary AAV capsid platform, JUST-AAV.” He also expressed his expectations that the platform could play a significant role in advancing gene therapies for rare conditions and emphasized the value of the company’s ongoing collaboration with Alexion.
The two companies have been partners since March 2023, when they began working together on a project focused on neurodegenerative disease using JCR’s J-Brain Cargo® technology. Their collaboration expanded in December 2023 to include the discovery of oligonucleotide therapies.
In addition to its work with JCR, Alexion acquired a portfolio of preclinical gene therapy programs from Pfizer in July 2023. That acquisition included multiple AAV assets. AstraZeneca previously aligned this deal with Alexion’s 2022 acquisition of genomic medicine company LogicBio.

JCR currently markets several pharmaceutical products in Japan, such as Izcargo, an enzyme replacement therapy used for Hunter syndrome, and Growject, a growth hormone treatment.
The new agreement marks the third collaborative initiative between JCR and Alexion. The companies describe it as a continuation of their existing partnership and a step toward applying the JUST-AAV platform more broadly.
JCR has incorporated the anticipated impact of this agreement into its consolidated financial forecast for the fiscal year ending March 31, 2026.